EuroBiotech—More Articles of Note

newspapers
(Pixabay)

> Themis Bioscience set the range for an Amsterdam IPO that could raise upward of €40 million ($46 million). Statement 

> Invectys raised €15 million to run a phase 2 trial of its DNA cancer vaccine. FiercePharma

> ProQr licensed the global rights to an ophthalmology drug candidate from Ionis. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Transgene teamed up with NEC to access an AI platform. Statement  

> The European Investment Bank agreed to loan Newron Pharmaceuticals up to €40 million. Release

Suggested Articles

In this week's EuroBiotech Report, GSK, Immatics strike cell therapy deal, Vifor buys priority review voucher and PharmaMar gets PDUFA date.

In our EuroBiotech roundup this week, U.K. creates life science zones, Genmab to ramp up R&D spending and Pfizer backs cancer biotech. 

Spruce Biosciences raised $88 million from the likes of Abingworth and Omega Funds to take the drug to the next level: a late-stage study in adults.